Acumen Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
From time to time, our officers (as defined in Rule 16a-1(f)) and directors may enter into Rule 10b5-1 ornon-Rule 10b5-1 trading plans (as each such term is defined in Item 408 of Regulation S-K). The trading plans are intended to satisfy the affirmative defense in Rule 10b5-1(c). During the three months ended September 30, 2025, our officers and directors took the following actions with respect to 10b5-1 trading plans:
On September 30, 2025, James Doherty, Ph.D., our President and Chief Development Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Doherty, acting through a broker, may sell the number of shares of common stock sufficient to cover the taxes, commissions and any fees associated with the vesting of up to 62,200 RSU awards granted to Dr. Doherty as equity compensation, which sales may occur from January 7, 2026 to December 29, 2028.
On September 30, 2025, Amy Schacterle, Ph.D., our Chief Regulatory Officer and Head of Quality, entered into a Rule 10b5-1 trading plan that provides that Dr. Schacterle, acting through a broker, may sell the number of shares of common stock sufficient to cover the taxes, commissions and any fees associated with the vesting of up to 8,800 RSU awards granted to Dr. Schacterle as equity compensation, which sales may occur from January 7, 2026 to December 29, 2028.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.